What Know Labs does

Know Labs is a Seattle-based medical technology company developing a proprietary non-invasive diagnostic platform based on Radio Frequency Dielectric Spectroscopy (Bio-RFID). The platform rapidly scans a wide range of RF frequencies (300 MHz to 4,400 MHz), recording voltage values across over 30,000 frequency/parameter combinations and collecting roughly 1.5 million data points per hour. These signals are processed by trade-secret machine learning algorithms, including a peer-reviewed LightGBM model, to quantify blood glucose and other analytes without needles, inserted transmitters, or disposable test strips. The flagship consumer product is the KnowU, a wearable continuous glucose monitor with a rechargeable battery designed to last years, paired with the GlucoseDashboard companion mobile application on iOS and Android. Know Labs complements its hardware roadmap with the Know Labs Technology Licensing (KTL) program, which licenses the underlying RFDS platform, SDKs, prototyping tools, and customizable AI models to enterprise partners across healthcare, industrial diagnostics, automotive, and consumer electronics.

The company's go-to-market strategy is product-led and follows two tracks: (1) direct-to-consumer distribution of the KnowU device via a companion mobile app following FDA clearance, with the company claiming pricing 3x-5x below incumbent CGM options, and (2) enterprise licensing through KTL enabling OEMs and partners to embed the RFDS technology across diverse form factors. Clinical validation has been conducted in collaboration with the Mayo Clinic and published in peer-reviewed venues including IEEE Sensors Journal and Diabetes Technology & Therapeutics. The product roadmap remains gated by FDA clearance, and the company has not yet generated commercial product revenue.

In August 2025, Know Labs underwent a fundamental strategic shift when Goldeneye 1995, LLC (an affiliate of Greg Kidd) acquired a controlling interest by contributing 1,000 Bitcoin and $15 million in cash for 357.8 million new common shares, valuing the company at approximately $125 million. Greg Kidd was appointed CEO and Chairman, the corporate name was changed to USBC, Inc., and the NYSE American ticker changed from KNW to USBC. The company now operates a dual-track strategy: a digital asset/fintech arm centered on the USBC token and a Bitcoin yield-generation treasury strategy, alongside a diagnostic research division under founder Ron Erickson pursuing non-invasive medical technology development. Know Labs is publicly listed (NYSE American: USBC, formerly KNW), holds 270+ patents issued, pending, or in-process worldwide, and employs between 11 and 50 people.

Name

Know Labs

Legal name

Know Labs, Inc.

Website

https://knowlabs.co

Company type

Public

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

Know Labs is a Seattle-based medical technology company developing the KnowU, a non-invasive wearable continuous glucose monitor built on proprietary RF Dielectric Spectroscopy (Bio-RFID) and AI, pursuing FDA clearance for direct-to-consumer use and licensing its sensing platform to enterprise partners via the KTL program.

Ownership category

akta.pro rank

Product category

Continuous Glucose Monitoring Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Instrument Manufacturing for Measuring and Testing Electricity and Electrical Signals (334515)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers) (CRACAQAE)

akta.pro secondary industries

Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK), Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI)

Keywords

• Non-invasive glucose monitoring
• Continuous glucose monitor
• Medical diagnostic devices
• RF spectroscopy sensors
• Wearable health technology

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Hardware Device Sales (KnowU): Sale of the KnowU non-invasive wearable continuous glucose monitor directly to consumers. The device is designed to last years and have a rechargeable battery, eliminating the need for costly disposables, making it a one-time hardware purchase with potential companion app subscription.
2. Companion Mobile App Subscription: The KnowU connects with a companion mobile app via Bluetooth providing real-time glucose monitoring and trend data, likely monetized through a recurring app subscription.
3. KTL IP and Technology Licensing: Know Labs Technology Licensing (KTL) program licenses the company's RFDS technology, patents, SDKs, and tools to third parties across healthcare, industrial diagnostics, automotive, and consumer electronics. Revenue is generated through licensing fees, SDK access fees, wet lab services, and phase-based engagement payments.
4. Digital Asset / Fintech (Post-Acquisition): Following the August 2025 acquisition by Greg Kidd/Goldeneye 1995, LLC, the company transitioned to include digital asset and fintech operations centered on the USBC token — a U.S.-dollar denominated digital token leveraging blockchain and digital identity technology that earns high-yield rewards. The company also retains a non-invasive diagnostic R&D division under founder Ron Erickson.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Know Labs develops proprietary non-invasive diagnostic hardware and software using Radio Frequency Dielectric Spectroscopy (Bio-RFID) to identify and measure molecules such as blood glucose without needles, inserted transmitters, or disposables. Its flagship product is the KnowU, a wearable continuous glucose monitor paired with a companion mobile app, alongside the KTL technology licensing program that offers its RFDS platform, SDKs, and IP to enterprise partners across healthcare, industrial, automotive, and consumer electronics.

Product overview

Know Labs offers a proprietary non-invasive medical diagnostic technology platform using Radio Frequency Dielectric Spectroscopy (Bio-RFID) to identify and measure molecules without needles or invasive transmitters. The core product is the KnowU, a wearable continuous glucose monitor (CGM) targeting the 2 billion people with diabetes and pre-diabetes. KnowU is a form-factor agnostic platform that can be integrated into wearable, mobile, or bench-top devices, featuring 3x-5x lower cost than current options and no disposables. The portfolio includes the companion GlucoseDashboard mobile app for iOS/Android, the Know Labs Technology Licensing (KTL) platform for third-party access to SDKs and IP licensing, and specialized data collection tools (Voltmeter, Carousel) for research applications.

Differentiator

Problem solved

Functional benefit

Brands

• KnowU: Non-invasive, wearable continuous blood glucose monitor designed to improve how people with diabetes and pre-diabetes manage their conditions.
• Know Labs Technology Licensing (KTL)
• Bio-RFID

Products and services

• KnowU Non-invasive wearable continuous glucose monitor using proprietary RF Dielectric Spectroscopy (Bio-RFID) technology. Worn with adhesive or strap on wrist/forearm, featuring rechargeable battery (24-hour continuous use), 256MB flash storage, BLE/Wi-Fi/USB-C connectivity, no disposables required, and designed to last for years. Pursuing FDA clearance.
• GlucoseDashboard Mobile App Companion mobile application for the KnowU device that provides real-time blood glucose monitoring, trend visualization, and advanced research capabilities. Connects via BLE and WiFi.
• Know Labs Technology Licensing (KTL) Licensing platform enabling partners to access RFDS technology, SDKs, wet lab support, prototyping tools, white-label mobile apps, and customizable AI/ML models. Backed by over 330 patents globally covering 100+ applications, with a phase-based engagement model.
• KTL Data Collection Tools (Voltmeter, Carousel) Research and development tools including 'Voltmeter' for data collection and 'Carousel' for high-volume testing of up to 12 samples simultaneously. Supports wet lab experiments for solids, liquids, and RF-related testing including depth, power, dielectrics, and material analysis.
• Portable Research System (Gen 1 Prototype) Portable research-grade RF sensor system featuring 256MB flash storage (40 hours offline research data), ultra-low power processor with onboard ML, BLE/WiFi/USB-C connectivity, and custom firmware. Distributed to clinical trial partners and research institutions.

Quantifiable outcome

• MARD of 12.7% in normoglycemic range and 14.0% in hyperglycemic range, validated via LightGBM AI model on 1,555 observations in peer-reviewed IEEE Sensors Journal study.
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

Partnerships

Three partnerships are on record, tiered core.

• Wyss Institute for Biologically Inspired Engineering at Harvard UniversitycoreStrategic or Co-development Partner · 5 June 2024Know Labs joined the Industrial Participant Program of the Wyss Institute at Harvard University in June 2024. This program provides access to cutting-edge research infrastructure and collaboration opportunities in biologically inspired engineering, supporting the company's non-invasive diagnostic technology development.
• Mayo CliniccoreStrategic or Co-development Partner · 21 April 2023Collaborative proof-of-principle study conducted with Mayo Clinic, demonstrating the accuracy of Know Labs' non-invasive Bio-RFID technology in quantifying different analytes in vitro. Results were peer-reviewed and published in the Sensors Journal and presented at the American Physiological Society 2023 Summit. This collaboration validated the foundational technology.
• KTL Licensee Partners (Unnamed)coreTechnology or IntegrationUnnamed industry partners across healthcare, industrial diagnostics, automotive, and consumer electronics engaging with the Know Labs Technology Licensing (KTL) platform to access RFDS technology, SDKs, wet lab support, and white-label solutions.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Dexcom: Market-leading continuous glucose monitor manufacturer (G6/G7), directly comparable to KnowU as a CGM addressing the same patient population with overlapping claims on accuracy and convenience. Dexcom is the accuracy benchmark against which Know Labs benchmarks its MARD.
• Senseonics Holdings: Developer of the Eversense implantable long-term CGM, the only peer attempting a fundamentally different sensing modality (fluorescence-based) for continuous glucose. Comparable to KnowU as a non-needle-free-disposables challenger CGM pursuing differentiated patient convenience claims.
• Abbott Diabetes Care (FreeStyle Libre): Abbott's FreeStyle Libre is the leading factory-calibrated flash CGM with a global installed base; comparable to KnowU in core analyte (interstitial glucose) but invasive via filament. Represents the dominant incumbent KnowU would seek to disrupt with a non-invasive modality.

Emerging players

• Alertgy: Early-stage company developing a non-invasive blood glucose monitor using electromagnetic/dielectric spectroscopy. Comparable to Know Labs' Bio-RFID approach in trying to deliver needle-free glucose monitoring, but at an earlier commercialization stage.
• Biolinq: Developer of a minimally invasive intradermal CGM patch focused on improving affordability and form-factor. Partially overlaps with KnowU around accessibility and wearability claims, though Biolinq retains a microneedle array.
• Movano Health: Building a non-invasive continuous glucose monitor using radio frequency technology in a wrist-worn form factor (Evie Ring). Closest emerging non-invasive CGM competitor to KnowU, pursuing many of the same over-the-counter and consumer-health use cases.

Broad incumbents

• LifeScan (OneTouch): OneTouch blood glucose monitoring brand competing in BGM; comparable to KnowU's first-generation consumer monitoring ambition but with a legacy strip-based model that KnowU's disposable-free economics could undercut.
• Ascensia Diabetes Care: Markets the CONTOUR blood glucose meter line globally, competing in patient-facing glucose monitoring. Comparable as a broader incumbent in adjacent BGM segments and a potential partner or competitor for KnowU in primary-care distribution.
• Medtronic Diabetes: Offers Guardian Connect CGM integrated with insulin pump ecosystems for Type 1 diabetes management. A broader incumbent across diabetes hardware, supplies, and software, with overlapping CGM capability but a much wider portfolio.
• Roche Diabetes Care: Long-established player offering Accu-Chek blood glucose meters, insulin delivery, and digital diabetes management. Comparable as a broad incumbent in glucose monitoring across BGM and adjacent software, even though it does not compete directly in CGM hardware.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/TheKnowLabs
• LinkedInlinkedin.com/company/knowlabsinc

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Know Labs